Augmedix, Inc.

    Augmedix, Inc.

    NNASDAQ:AUGX
    2.35
    USD
    0.00
    (0.00%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    0.53
    0.61
    0.59
    0.83
    1.02
    1.03
    Basic EPS, GAAP
    -0.69
    -0.58
    -0.47
    -0.65
    -0.44
    -0.47
    Free Cash Flow per Basic Share
    -0.58
    -0.56
    -0.51
    -0.49
    -0.42
    -0.36
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -2.54
    -3.12
    -2.71
    -3.36
    -3.3
    -3.18
    Tangible Book Value per Share
    -2.42
    0.12
    0.64
    0.04
    0.53
    0.21
    Basic Weighted Avg Shares
    27
    27
    37
    37
    44
    50
    Sales/Revenue/Turnover
    14
    16
    22
    31
    45
    52
    Operating Margin (%)
    -118.68
    -83.07
    -79.18
    -72.32
    -41.87
    -46.29
    Depreciation Expense
    1
    1
    1
    1
    1
    1
    Net Income, GAAP
    -18
    -16
    -17
    -24
    -19
    -24
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -131.12
    -94.67
    -78.79
    -79.04
    -42.74
    -46.23
    Working Capital
    1
    10
    37
    10
    33
    16
    LT Debt
    10
    8
    13
    12
    19
    19
    Total Equity
    -65
    3
    24
    1
    23
    10
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    ST Debt
    6
    9
    6
    LT Borrowings
    15
    13
    16
    LT Finance Leases
    4
    4
    3
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    49
    49
    49
    Market Capitalization
    257
    196
    44

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    Total Current Assets
    57
    50
    40
    Cash, Cash Equivalents & STI
    46
    37
    28
    Accounts Receivable, Net
    9
    10
    9
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    24
    25
    24
    Payables & Accruals
    3
    4
    5
    ST Debt
    6
    9
    6
    Deferred Revenue
    10
    10
    10

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    - -
    1,490.79%
    Free Cash Flow
    - -
    - -
    2.01%
    Net Income, GAAP
    - -
    - -
    -21.59%
    Sales/Revenue/Turnover
    - -
    - -
    45.01%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    7
    7
    8
    9
    31
    2023
    10
    11
    12
    13
    45
    2024
    13
    14
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.16
    -0.2
    -0.15
    -0.15
    -0.65
    2023
    -0.14
    -0.12
    -0.1
    -0.09
    -0.44
    2024
    -0.12
    -0.16
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Veradigm (NASDAQ:MDRX) & Augmedix (OTCMKTS:AUGX) Financial Comparison

    • globenewswire.com

      Commure Completes Merger with Augmedix

    • 247wallst.com

      7 AI Penny Stocks to Watch in October

    • prnewswire.com

      STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger and Looming Vote on September 27, 2024, of Augmedix, Inc. - AUGX

    • zacks.com

      Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

    • globenewswire.com

      Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

    • globenewswire.com

      STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Augmedix, Inc. – AUGX

    • investorplace.com

      Why Is Augmedix (AUGX) Stock Up 150% Today?

    • prnewswire.com

      Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

    • globenewswire.com

      Augmedix to Join Forces with Commure

    • globenewswire.com

      Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments

    • globenewswire.com

      Augmedix Reiterates Second Quarter and Full Year 2024 Outlook

    • globenewswire.com

      Augmedix Appoints Alex Stinard, M.D., as Chief Clinical AI Officer

    • investorplace.com

      Why Is Augmedix (AUGX) Stock Down 41% Today?

    • seekingalpha.com

      Augmedix, Inc. (AUGX) Q1 2024 Earnings Call Transcript

    • globenewswire.com

      Augmedix Delivers 40% Revenue Growth for First Quarter of 2024

    • globenewswire.com

      Augmedix to Participate in Upcoming Investor Conferences in May and June 2024

    • globenewswire.com

      Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

    • investorplace.com

      3 Penny Stocks That Could Make a Big Comeback by the End of Q2

    • globenewswire.com

      Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care